Stockholders approve share authorization and 19.99%-or-more issuance
At its November 11, 2026 Special Meeting, GT Biopharma stockholders approved all four proposals, including elimination of obsolete preferred-stock charter references, an increase in authorized common stock from 25,000,000 to 250,000,000, and approval, for purposes of Nasdaq Rule 5635, of the issuance of 19.99% or more of outstanding common stock in connection with a September 14, 2026 Securities Purchase Agreement, Series M Preferred Stock conversion, and warrant exercises. Stockholders also approved an adjournm...
Key takeaways
All four proposals were approved at the November 11, 2026 Special Meeting.
Stockholders approved increasing authorized common stock from 25,000,000 to 250,000,000, with the higher ceiling available at any time on or before November 11, 2027.
Stockholders approved, for Nasdaq Rule 5635 purposes, the potential issuance of 19.99% or more of outstanding common stock tied to the September 14, 2026 Securities Purchase Agreement, Series M Preferred Stock conversion, and exercise of Common Stock Warrants and Vesting Warrants.
The filing does not disclose the amount, pricing, or exact number of shares issuable under the approved issuance.
Stockholders approved removal of charter references to preferred-stock series that are no longer designated, issued, or outstanding.
The meeting had a quorum, with 1,146,416 shares represented in person or by proxy, or approximately 55.62% of 2,061,052 eligible shares.
Stockholders also approved meeting adjournment authority if a quorum had not been established or other proposals lacked sufficient votes.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow GTBP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.